Join
Live feed
·
PRReleasevia Quantisnow
Lantern Pharma Inc. logo

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

ByQuantisnow·Wall Street's wire, on your screen.
LTRN· Lantern Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LTRN (Lantern Pharma Inc.) and more on Quantisnow.